Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

A study led by researchers at Johns Hopkins Bloomberg School of Public Health in the US found that the median incubation period of the novel coronavirus could be five days.

The study involved a review of publicly available data on 181 Covid-19 cases detected in China and other countries before 24 February.

Majority of the cases travelled to or from Wuhan, China or came in contact with people who had been to Hubei province.

The analysis of the data reveals that approximately 97.5% of infected patients will develop symptoms within 11.5 days of exposure.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Based on this finding, the researchers concluded that the current 14-day quarantine period used by the US CDC and health authorities in other countries is reasonable.

However, a longer quarantine period might be required in certain cases as 101 out of every 10,000 quarantined individuals would develop symptoms after the 14-day period.

Bloomberg School epidemiology department associate professor Justin Lessler said: “Based on our analysis of publicly available data, the current recommendation of 14 days for active monitoring or quarantine is reasonable, although with that period some cases would be missed over the long-term.”

An accurate estimation of the incubation period will allow effective quarantine and other measures to control the spread of the virus.

Previous studies by Chinese researchers showed that the coronavirus incubation period could be as long as 27 days. Another study found the median incubation period to be three days, with a range of zero to 24 days.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact